Allogene Total Stockholder Equity vs Short Long Term Debt Total Analysis

ALLO Stock

USD 2.14 0.05 2.28%

Allogene Therapeutics financial indicator trend analysis is way more than just evaluating Allogene Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Allogene Therapeutics is a good investment. Please check the relationship between Allogene Therapeutics Total Stockholder Equity and its Short Long Term Debt Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.

Total Stockholder Equity vs Short Long Term Debt Total

Total Stockholder Equity vs Short Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Allogene Therapeutics Total Stockholder Equity account and Short Long Term Debt Total. At this time, the significance of the direction appears to have strong relationship.

The correlation between Allogene Therapeutics' Total Stockholder Equity and Short Long Term Debt Total is 0.64. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Allogene Therapeutics, assuming nothing else is changed. The correlation between historical values of Allogene Therapeutics' Total Stockholder Equity and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Allogene Therapeutics are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Total Stockholder Equity i.e., Allogene Therapeutics' Total Stockholder Equity and Short Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

0.64

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Short Long Term Debt Total

Most indicators from Allogene Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Allogene Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.As of the 12th of December 2024, Sales General And Administrative To Revenue is likely to grow to 792.18, while Selling General Administrative is likely to drop about 61.1 M.

	2021	2022	2023	2024 (projected)
Interest Income	1.7M	4.6M	14.8M	15.5M
Net Interest Income	1.7M	4.6M	14.8M	9.2M

Interest Income Net Interest Income

Allogene Therapeutics fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Net Invested Capital	Net Working Capital	Common Stock	Short Long Term Debt Total	Other Liab	Property Plant And Equipment Net	Net Debt	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Retained Earnings Total Equity	Capital Surpluse	Capital Lease Obligations	Inventory	Other Current Assets	Property Plant And Equipment Gross
Other Current Liab		0.97	0.97	0.97	-0.8	0.94	0.24	0.93	0.98	0.97	0.96	0.94	0.77	-0.84	0.92	0.23	0.57	-0.31	0.04	0.13	-0.87	0.84	0.76	0.79	0.81	0.85
Total Current Liabilities	0.97		0.95	0.94	-0.71	0.87	0.19	0.86	0.94	0.95	0.96	0.87	0.67	-0.79	0.86	0.11	0.75	-0.27	0.2	0.05	-0.79	0.79	0.66	0.64	0.75	0.81
Total Stockholder Equity	0.97	0.95		0.99	-0.71	0.93	0.03	0.83	0.94	1.0	0.97	0.93	0.64	-0.74	0.82	0.15	0.57	-0.28	0.12	0.17	-0.78	0.74	0.63	0.71	0.73	0.73
Net Tangible Assets	0.97	0.94	0.99		-0.78	0.97	0.1	0.88	0.96	0.99	0.98	0.96	0.71	-0.79	0.85	0.26	0.55	-0.34	0.03	0.09	-0.81	0.8	0.7	0.74	0.75	0.78
Retained Earnings	-0.8	-0.71	-0.71	-0.78		-0.85	-0.51	-0.92	-0.88	-0.71	-0.73	-0.88	-0.96	0.97	-0.91	-0.73	-0.21	0.7	0.45	0.09	0.95	-0.91	-0.95	-0.85	-0.74	-0.93
Common Stock Total Equity	0.94	0.87	0.93	0.97	-0.85		0.17	0.92	0.97	0.93	0.94	1.0	0.82	-0.85	0.88	0.41	0.39	-0.38	-0.2	0.0	-0.85	0.84	0.81	0.83	0.8	0.85
Common Stock Shares Outstanding	0.24	0.19	0.03	0.1	-0.51	0.17		0.53	0.29	0.03	0.05	0.18	0.61	-0.55	0.56	0.37	0.12	-0.29	-0.24	0.03	-0.57	0.61	0.6	0.48	0.35	0.59
Other Stockholder Equity	0.93	0.86	0.83	0.88	-0.92	0.92	0.53		0.96	0.83	0.84	0.92	0.93	-0.94	0.98	0.44	0.44	-0.41	-0.19	0.06	-0.96	0.97	0.92	0.88	0.82	0.96
Total Liab	0.98	0.94	0.94	0.96	-0.88	0.97	0.29	0.96		0.94	0.95	0.97	0.86	-0.91	0.94	0.36	0.49	-0.38	-0.12	0.03	-0.91	0.89	0.85	0.82	0.82	0.92
Net Invested Capital	0.97	0.95	1.0	0.99	-0.71	0.93	0.03	0.83	0.94		0.97	0.93	0.64	-0.74	0.82	0.15	0.57	-0.28	0.12	0.17	-0.78	0.74	0.63	0.71	0.73	0.73
Net Working Capital	0.96	0.96	0.97	0.98	-0.73	0.94	0.05	0.84	0.95	0.97		0.94	0.67	-0.79	0.81	0.23	0.6	-0.32	0.03	-0.05	-0.75	0.73	0.66	0.7	0.82	0.76
Common Stock	0.94	0.87	0.93	0.96	-0.88	1.0	0.18	0.92	0.97	0.93	0.94		0.84	-0.87	0.88	0.46	0.37	-0.44	-0.23	-0.02	-0.86	0.85	0.83	0.83	0.81	0.85
Short Long Term Debt Total	0.77	0.67	0.64	0.71	-0.96	0.82	0.61	0.93	0.86	0.64	0.67	0.84		-0.94	0.93	0.65	0.15	-0.52	-0.48	-0.04	-0.94	0.93	1.0	0.87	0.74	0.96
Other Liab	-0.84	-0.79	-0.74	-0.79	0.97	-0.85	-0.55	-0.94	-0.91	-0.74	-0.79	-0.87	-0.94		-0.94	-0.65	-0.35	0.64	0.37	0.17	0.94	-0.9	-0.94	-0.85	-0.85	-0.96
Property Plant And Equipment Net	0.92	0.86	0.82	0.85	-0.91	0.88	0.56	0.98	0.94	0.82	0.81	0.88	0.93	-0.94		0.41	0.41	-0.42	-0.16	0.15	-0.98	0.95	0.92	0.88	0.79	0.96
Net Debt	0.23	0.11	0.15	0.26	-0.73	0.41	0.37	0.44	0.36	0.15	0.23	0.46	0.65	-0.65	0.41		-0.32	-0.87	-0.86	-0.45	-0.51	0.45	0.64	0.56	0.46	0.51
Other Assets	0.57	0.75	0.57	0.55	-0.21	0.39	0.12	0.44	0.49	0.57	0.6	0.37	0.15	-0.35	0.41	-0.32		0.03	0.65	-0.09	-0.31	0.42	0.14	0.06	0.35	0.4
Long Term Debt	-0.31	-0.27	-0.28	-0.34	0.7	-0.38	-0.29	-0.41	-0.38	-0.28	-0.32	-0.44	-0.52	0.64	-0.42	-0.87	0.03		0.53	0.36	0.53	-0.42	-0.5	-0.45	-0.4	-0.46
Cash And Short Term Investments	0.04	0.2	0.12	0.03	0.45	-0.2	-0.24	-0.19	-0.12	0.12	0.03	-0.23	-0.48	0.37	-0.16	-0.86	0.65	0.53		0.43	0.24	-0.17	-0.48	-0.43	-0.32	-0.27
Net Receivables	0.13	0.05	0.17	0.09	0.09	0.0	0.03	0.06	0.03	0.17	-0.05	-0.02	-0.04	0.17	0.15	-0.45	-0.09	0.36	0.43		-0.17	0.08	-0.04	0.16	-0.25	-0.07
Retained Earnings Total Equity	-0.87	-0.79	-0.78	-0.81	0.95	-0.85	-0.57	-0.96	-0.91	-0.78	-0.75	-0.86	-0.94	0.94	-0.98	-0.51	-0.31	0.53	0.24	-0.17		-0.95	-0.94	-0.89	-0.73	-0.94
Capital Surpluse	0.84	0.79	0.74	0.8	-0.91	0.84	0.61	0.97	0.89	0.74	0.73	0.85	0.93	-0.9	0.95	0.45	0.42	-0.42	-0.17	0.08	-0.95		0.92	0.79	0.66	0.96
Capital Lease Obligations	0.76	0.66	0.63	0.7	-0.95	0.81	0.6	0.92	0.85	0.63	0.66	0.83	1.0	-0.94	0.92	0.64	0.14	-0.5	-0.48	-0.04	-0.94	0.92		0.87	0.74	0.96
Inventory	0.79	0.64	0.71	0.74	-0.85	0.83	0.48	0.88	0.82	0.71	0.7	0.83	0.87	-0.85	0.88	0.56	0.06	-0.45	-0.43	0.16	-0.89	0.79	0.87		0.83	0.8
Other Current Assets	0.81	0.75	0.73	0.75	-0.74	0.8	0.35	0.82	0.82	0.73	0.82	0.81	0.74	-0.85	0.79	0.46	0.35	-0.4	-0.32	-0.25	-0.73	0.66	0.74	0.83		0.76
Property Plant And Equipment Gross	0.85	0.81	0.73	0.78	-0.93	0.85	0.59	0.96	0.92	0.73	0.76	0.85	0.96	-0.96	0.96	0.51	0.4	-0.46	-0.27	-0.07	-0.94	0.96	0.96	0.8	0.76

Click cells to compare fundamentals

Allogene Therapeutics Account Relationship Matchups

Allogene Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	717.8M	1.2B	1.0B	817.1M	642.8M	820.0M
Other Current Liab	23.8M	42.0M	34.7M	33.7M	24.3M	27.6M
Total Current Liabilities	33.1M	94.3M	48.2M	54.5M	37.1M	46.6M
Total Stockholder Equity	629.0M	1.1B	916.4M	665.9M	512.2M	708.1M
Net Tangible Assets	628.9M	1.1B	916.4M	665.9M	765.8M	732.1M
Retained Earnings	(396.1M)	(646.3M)	(903.3M)	(1.2B)	(1.6B)	(1.5B)
Accounts Payable	9.3M	10.4M	10.3M	13.9M	5.9M	9.7M
Cash	588.9M	1.0B	809.5M	576.5M	83.2M	79.0M
Non Current Assets Total	173.2M	382.7M	229.2M	288.3M	183.7M	245.6M
Non Currrent Assets Other	8.9M	14.6M	(322.1M)	32.7M	16.9M	17.7M
Common Stock Total Equity	121K	124K	140K	142K	163.3K	121.7K
Common Stock Shares Outstanding	101.1M	120.4M	135.8M	143.1M	156.9M	125.7M
Short Term Investments	355.4M	644.6M	284.0M	455.4M	365.5M	388.4M
Non Current Liabilities Total	55.7M	53.9M	74.1M	96.7M	93.5M	65.2M
Other Stockholder Equity	1.0B	1.7B	1.8B	1.9B	2.1B	1.4B
Total Liab	88.8M	148.2M	122.2M	151.2M	130.6M	111.8M
Net Invested Capital	629.0M	1.1B	916.4M	665.9M	512.2M	708.1M
Long Term Investments	63.2M	204.2M	352.2M	72.0M	3.6M	3.5M
Total Current Assets	544.6M	845.1M	809.5M	528.8M	459.1M	574.4M
Net Working Capital	511.5M	750.8M	423.1M	474.3M	422.0M	474.6M
Common Stock	124K	140K	142K	144K	169K	136.1K
Short Long Term Debt Total	51.3M	53.8M	69.9M	95.1M	95.1M	73.3M
Other Liab	4.4M	3.1M	4.1M	1.6M	1.4M	1.3M
Property Plant And Equipment Net	100.9M	160.1M	181.0M	196.4M	163.2M	154.6M
Net Debt	(537.5M)	(978.3M)	(739.6M)	(481.3M)	12.0M	12.6M
Other Assets	8.9M	263.9M	16.1M	16.9M	19.4M	18.4M
Cash And Short Term Investments	588.9M	1.0B	809.5M	576.5M	448.7M	556.9M
Net Receivables	2.4M	2.8M	6M	3.3M	1.7M	2.6M
Liabilities And Stockholders Equity	717.8M	1.2B	1.0B	817.1M	642.8M	695.7M
Capital Lease Obligations	51.3M	53.8M	69.9M	101.1M	95.1M	74.4M
Inventory	(60.7M)	(207.0M)	(20.0M)	(62.5M)	(71.8M)	(75.4M)
Other Current Assets	14.0M	10.6M	8.0M	11.5M	10.4M	11.0M
Property Plant And Equipment Gross	56.4M	160.1M	123.0M	233.3M	214.3M	145.9M
Accumulated Other Comprehensive Income	1.1M	268K	(2.6M)	(9.9M)	(955K)	(1.0M)
Capital Stock	124K	140K	142K	144K	169K	154K
Non Current Liabilities Other	4.4M	53.9M	74.1M	1.6M	5.2M	4.9M
Property Plant Equipment	100.9M	118.8M	123.0M	196.4M	225.9M	127.8M

Pair Trading with Allogene Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allogene Stock

0.67	VALN	Valneva SE ADR	Pair Corr
0.74	ERNA	Eterna Therapeutics	Pair Corr

Moving against Allogene Stock

0.61	DYAI	Dyadic International	Pair Corr
0.57	BMY	Bristol Myers Squibb	Pair Corr
0.56	ESPR	Esperion Therapeutics	Pair Corr

The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.

The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:

How To Invest In Allogene

Details

Is Allogene Stock a good investment?

Details

What is Allogene Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.

You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.55)

Quarterly Revenue Growth

(0.27)

Return On Assets

(0.26)

Return On Equity

(0.54)

The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Allogene Total Stockholder Equity vs Short Long Term Debt Total Analysis

Total Stockholder Equity vs Short Long Term Debt Total

Total Stockholder Equity vs Short Long Term Debt Total Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Short Long Term Debt Total

Allogene Therapeutics fundamental ratios Correlations

Allogene Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Allogene Therapeutics fundamental ratios Accounts

Pair Trading with Allogene Therapeutics

Moving together with Allogene Stock

Moving against Allogene Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Common Stock	+ 1.0	Common Stock Total Equity
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Net Invested Capital	+ 0.99	Net Tangible Assets
Total Liab	+ 0.98	Other Current Liab

Retained Earnings Total Equity	- 0.98	Property Plant And Equipment Net
Property Plant And Equipment Gross	- 0.96	Other Liab
Retained Earnings Total Equity	- 0.96	Other Stockholder Equity
Short Long Term Debt Total	- 0.96	Retained Earnings
Capital Surpluse	- 0.95	Retained Earnings Total Equity
Capital Lease Obligations	- 0.95	Retained Earnings